Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Adjustments to Financial Statements

Microsoft Excel

Adjustments to Current Assets

Thermo Fisher Scientific Inc., adjusted current assets

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Current assets 24,589 25,229 20,113 21,957 11,893
Adjustments
Add: Allowances 193 189 150 135 102
Add: LIFO reserve1 49 39
After Adjustment
Adjusted current assets 24,782 25,418 20,263 22,141 12,034

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 LIFO reserve. See details »


Adjustments to Total Assets

Thermo Fisher Scientific Inc., adjusted total assets

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Total assets 98,726 97,154 95,123 69,052 58,381
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1
Add: Allowances 193 189 150 135 102
Add: LIFO reserve2 49 39
Less: Deferred tax assets3 831 865 1,008 689 573
After Adjustment
Adjusted total assets 98,088 96,478 94,265 68,547 57,949

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 LIFO reserve. See details »

3 Deferred tax assets. See details »


Adjustments to Current Liabilities

Thermo Fisher Scientific Inc., adjusted current liabilities

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Current liabilities 14,012 17,010 13,436 10,304 6,197
Adjustments
Less: Current accrued restructuring costs 60 41 17 21 34
After Adjustment
Adjusted current liabilities 13,952 16,969 13,419 10,283 6,163

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


Adjustments to Total Liabilities

Thermo Fisher Scientific Inc., adjusted total liabilities

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Total liabilities 51,884 53,006 54,146 34,535 28,706
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1
Less: Deferred tax liabilities2 1,922 2,849 3,837 1,794 2,192
Less: Accrued restructuring costs 60 41 17 21 34
After Adjustment
Adjusted total liabilities 49,902 50,116 50,292 32,720 26,480

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Deferred tax liabilities. See details »


Adjustments to Stockholders’ Equity

Thermo Fisher Scientific Inc., adjusted total Thermo Fisher Scientific Inc. shareholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Total Thermo Fisher Scientific Inc. shareholders’ equity 46,735 43,978 40,793 34,507 29,675
Adjustments
Less: Deferred tax assets (liabilities), net1 (1,091) (1,984) (2,829) (1,105) (1,619)
Add: Allowances 193 189 150 135 102
Add: LIFO reserve2 49 39
Add: Accrued restructuring costs 60 41 17 21 34
Add: Redeemable noncontrolling interest 118 116 122
Add: Noncontrolling interests (11) 54 62 10
After Adjustment
Adjusted total equity 48,186 46,362 43,973 35,827 31,469

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Deferred tax assets (liabilities), net. See details »

2 LIFO reserve. See details »


Adjustments to Capitalization Table

Thermo Fisher Scientific Inc., adjusted capitalization table

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Short-term obligations and current maturities of long-term obligations 3,609 5,579 2,537 2,628 676
Long-term obligations, excluding current maturities 31,308 28,909 32,333 19,107 17,076
Total reported debt 34,917 34,488 34,870 21,735 17,752
Total Thermo Fisher Scientific Inc. shareholders’ equity 46,735 43,978 40,793 34,507 29,675
Total reported capital 81,652 78,466 75,663 56,242 47,427
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1
Add: Operating lease liabilities, current (included in Other accrued expenses)2 263 272 266 184 167
Add: Operating lease liabilities, noncurrent (included in Other long-term liabilities)3 1,244 1,313 1,203 626 571
Adjusted total debt 36,424 36,073 36,339 22,545 18,490
Adjustments to Equity
Less: Deferred tax assets (liabilities), net4 (1,091) (1,984) (2,829) (1,105) (1,619)
Add: Allowances 193 189 150 135 102
Add: LIFO reserve5 49 39
Add: Accrued restructuring costs 60 41 17 21 34
Add: Redeemable noncontrolling interest 118 116 122
Add: Noncontrolling interests (11) 54 62 10
Adjusted total equity 48,186 46,362 43,973 35,827 31,469
After Adjustment
Adjusted total capital 84,610 82,435 80,312 58,372 49,959

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Operating lease liabilities, current (included in Other accrued expenses). See details »

3 Operating lease liabilities, noncurrent (included in Other long-term liabilities). See details »

4 Deferred tax assets (liabilities), net. See details »

5 LIFO reserve. See details »


Adjustments to Reported Income

Thermo Fisher Scientific Inc., adjusted net income attributable to Thermo Fisher Scientific Inc.

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Net income attributable to Thermo Fisher Scientific Inc. 5,995 6,950 7,725 6,375 3,696
Adjustments
Add: Deferred income tax expense (benefit)1 (1,300) (997) (645) (269) (499)
Add: Increase (decrease) in allowances 4 39 15 33 (15)
Add: Increase (decrease) in LIFO reserve2 (49) 10 5
Add: Increase (decrease) in accrued restructuring costs 19 24 (4) (13) (46)
Add: Other comprehensive income (loss) (133) (777) 478 (128) (180)
Add: Comprehensive income (loss), net of tax, attributable to noncontrolling interest (48) 3 2 2 3
After Adjustment
Adjusted net income 4,537 5,242 7,522 6,010 2,964

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Deferred income tax expense (benefit). See details »

2 Increase (decrease) in LIFO reserve. See details »